These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 9468366)

  • 1. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
    Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
    AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic vaccination with p24-VLP and zidovudine augments HIV-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals.
    Benson EM; Clarkson J; Law M; Marshall P; Kelleher AD; Smith DE; Patou G; Stewart GJ; Cooper DA; French RA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):105-13. PubMed ID: 10029243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
    Peters BS; Cheingsong-Popov R; Callow D; Foxall R; Patou G; Hodgkin K; Weber JN
    J Infect; 1997 Nov; 35(3):231-5. PubMed ID: 9459393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline.
    Smith D; Gow I; Colebunders R; Weller I; Tchamouroff S; Weber J; Boag F; Hales G; Adams S; Patou G; Cooper DA;
    HIV Med; 2001 Oct; 2(4):272-5. PubMed ID: 11737409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
    Krown SE; Aeppli D; Balfour HH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
    Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
    AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
    Lindenburg CE; Stolte I; Langendam MW; Miedema F; Williams IG; Colebunders R; Weber JN; Fisher M; Coutinho RA
    Vaccine; 2002 May; 20(17-18):2343-7. PubMed ID: 12009290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
    Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
    AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
    Carr A; Vella S; de Jong MD; Sorice F; Imrie A; Boucher CA; Cooper DA
    AIDS; 1996 Jun; 10(6):635-41. PubMed ID: 8780818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of specific T-cell responses in HIV infection.
    Leandersson AC; Bratt G; Hinkula J; Gilljam G; Cochaux P; Samson M; Sandström E; Wahren B
    AIDS; 1998 Jan; 12(2):157-66. PubMed ID: 9468364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups.
    Ragni MV; Amato DA; LoFaro ML; DeGruttola V; Van Der Horst C; Eyster ME; Kessler CM; Gjerset GF; Ho M; Parenti DM
    Blood; 1995 May; 85(9):2337-46. PubMed ID: 7727768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons.
    Veenstra J; Williams IG; Colebunders R; Dorrell L; Tchamouroff SE; Patou G; Lange JM; Weller IV; Goeman J; Uthayakumar S; Gow IR; Weber JN; Coutinho RA
    J Infect Dis; 1996 Oct; 174(4):862-6. PubMed ID: 8843231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
    AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
    AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.